Pathological features and survival of triple positive breast cancer in 271 cases
10.3969/j.issn.1009-9905.2018.04.003
- VernacularTitle:三阳性乳腺癌271例临床病理特征与生存分析
- Author:
Xiao-Qing GUAN
1
;
Shu-Cheng GU
;
Ji WU
;
Xiao-Ling JIANG
;
Xiao-Hong SHI
;
Mu YUAN
;
Bo-Lin LU
;
Xing QIU
;
Zhen YUAN
;
Xiang-Xin ZHENG
Author Information
1. 徐州医科大学附属宿迁医院甲乳外科 江苏 宿迁223800
- Keywords:
Triple positive breast cancer;
Pathological feature;
Disease-free survival;
Overall survival
- From:
Chinese Journal of Current Advances in General Surgery
2018;21(4):262-266
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore pathological features and survival of triple positive breast cancer (TPBC).Methods:The clinical data of 271 cases of triple positive breast cancer from January 2010 to January 2017 in Suqian area were collected,compared with 283 cases of Luminal B I (HER2 negative).The clinical pathological features and survival were analyzed.Results:Among 271 cases of triple positive breast cancer,there were 89 cases (32.84％) of distant recurrence and metastasis in 2 years,and 137 cases (50.55％) of distant recurrence in 5 years.Among 283 cases of Luminal B I,there were 32 cases (11.31 ％) of distant recurrence and metastasis in 2 years.and 52 cases (18.37％) of distant recurrence in 5 years.There were significantly differences(P＜0.05).1 year Disease-free survival (DFS)and Overall survival (OS) of all patients were 100％,Among 271 cases of triple positive breast cancer,2-year DFS and OS were 64.94 ％,85.24％ respectively.3-year DFS and OS were 54.98 ％,69.74％ respectively,5-year DFS and OS were 43.54％,47.23％ respectively.Among 283 cases of Luminal B I,2-year DFS and OS were 86.22 ％,95.76％ respectively.3-year DFS and OS were 81.98 ％,80.92％ respectively,5-year DFS and OS were 76.33％,67.49％ respectively.There were significantly differences(P＜0.05).Conclusion:TPBC has the characteristics of poor biological behavior,large mass,pathological grade of grade Ⅲ,vascular or nerve infiltration,axillary lymph node metastasis,high proliferation index and high tumor load,and early distant recurrence,low DFS and OS.We Should choose individualized,targeted treatment programs,based on patient's hormone receptor and Ki67 expression,so as to benefit patients of TPBC.
